The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up.
The device uses “gentle, controlled puffs of air in the ears” to subtly change pressure in the external ear canal, a drug-free technology that Nocira calls Automated Variable Pulse Insufflation (AVPI).
Get the full story at our sister site, Medical Design & Outsourcing.
Filed Under: Blog, Clinical Trials, Featured, Food & Drug Administration (FDA), Neurological, Neuromodulation/Neurostimulation, News Well, Pain Management, Regulatory/Compliance Tagged With: FDA, migraines, Nocira
Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.